100
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

, , , , ORCID Icon, , , , & show all
Pages 6093-6099 | Published online: 27 Sep 2021

References

  • Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2018;59(2):274–287. doi:10.1080/10428194.2017.1330956
  • Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017;31(2):43–62. doi:10.1016/j.blre.2016.09.005
  • Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541–2552. doi:10.1200/JCO.2014.55.1564
  • Soura EN, Karikas GA. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients. J BUON. 2019;24(4):1326–1339.
  • Klepin HD. Elderly acute myeloid leukemia: assessing risk. Curr Hematol Malig Rep. 2015;10(2):118–125. doi:10.1007/s11899-015-0257-2
  • Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71(3):238–244.
  • Liu J, Jia JS, Gong LZ, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC. Zhonghua Xue Ye Xue Za Zhi. 2018;39(9):734–738.
  • Ebbo M, Riviere E, Godeau B. Adult immune thrombocytopenia and thrombopoietin receptor agonist: ten years later. Rev Med Interne. 2020;S0248-8663:30208.
  • Chelvatheebam S, Langabeer SE, Linch DC, Hills RK, Greenwell P. Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia. Leuk Res. 2003;27(9):869–870. doi:10.1016/S0145-2126(03)00016-X
  • Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res. 2007;31(10):1383–1388.
  • Kaushansky K. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. Thromb J. 2016;14(Suppl 1):40. doi:10.1186/s12959-016-0095-z
  • Ayala RM, Martinez-Lopez J, Albizua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol. 2009;84(2):79–86. doi:10.1002/ajh.21332
  • Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94(11):3694–3701. doi:10.1182/blood.V94.11.3694
  • Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000;9(8):2530–2535. doi:10.1182/blood.V95.8.2530
  • Perl AE. Which novel agents will have a clinically meaningful impact in AML at diagnosis? Best Pract Res Clin Haematol. 2021;34(1):101257. doi:10.1016/j.beha.2021.101257
  • Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6(8):6448–6458. doi:10.18632/oncotarget.3361
  • Minakata D, Fujiwara S, Ito S, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82–87. doi:10.1016/j.leukres.2015.12.013
  • Suzushima H, Wada N, Yamasaki H, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leuk Res. 2010;34(5):610–614. doi:10.1016/j.leukres.2009.08.010
  • Hirayama Y, Sakamaki S, Takayanagi N, et al. [Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients–effects, complications and long-term survival]. Gan To Kagaku Ryoho. 2003;30(8):1113–1118. Japanese